Date: 2013-12-30
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Abbvie (USA - IL)
Product: veliparib (ABT-888)
Action
mechanism: poly ADP ribose polymerase PARP inhibitor/PARP inhibitor. Veliparib is an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor being evaluated in multiple tumor types. PARP is a naturally-occurring enzyme in the body that repairs damage to DNA, and in certain types of cancers, repairs cancer cells. Discovered by AbbVie researchers, veliparib is being developed to help prevent DNA repair in cancer cells and increase the effectiveness of common DNA-damaging therapies like chemotherapy or radiation.
Veliparib is currently being studied in more than a dozen cancers and tumor types, including Phase 3 studies in non-small cell lung cancer and breast cancer.
Disease: triple-negative breast cancer (TNBC)
Therapeutic area: Cancer - Oncology
Country: Australia, Belgium, Canada, Czech Republic, France, Germany, Hungary, Italy, Republic of Korea, Netherlands, Russian Federation, Spain, Taiwan, UK, USA, Israel, Poland
Trial
details: This 3 arm Phase 3 study is evaluating the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC. (NCT02032277)
Latest
news: * On December 13, 2013, a new Phase 3 trial with veliparib, an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor was published on ClinicalTrials.gov " A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer".
